The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter
about
MDM2 negatively regulates the human telomerase RNA gene promoterTranscription factor TAFII250 promotes Mdm2-dependent turnover of p53TAF1 differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating and -conjugating domainsCharacterization of human constitutive photomorphogenesis protein 1, a RING finger ubiquitin ligase that interacts with Jun transcription factors and modulates their transcriptional activityCyclin A-CDK phosphorylates Sp1 and enhances Sp1-mediated transcription.High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistanceInteraction between the transcription factor SPBP and the positive cofactor RNF4. An interplay between protein binding zinc fingersIdentification of a CK2 phosphorylation site in mdm2.Cirrhotic livers reveal genetic changes in the MDM2-P14ARF system of cell cycle regulatorsMolecular interaction map of the mammalian cell cycle control and DNA repair systems.Regulation of p53 stability.Regulation of the mdm2 oncogene by thyroid hormone receptorRequirement for TAF(II)250 acetyltransferase activity in cell cycle progression.Defect in the p53-Mdm2 autoregulatory loop resulting from inactivation of TAF(II)250 in cell cycle mutant tsBN462 cells.Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stressThe central region of HDM2 provides a second binding site for p53.Evidence that the human cytomegalovirus IE2-86 protein binds mdm2 and facilitates mdm2 degradationMDM2 regulates estrogen receptor α and estrogen responsiveness in breast cancer cellsInhibiting the p53-MDM2 interaction: an important target for cancer therapy.Induction of MDM2-P2 transcripts correlates with stabilized wild-type p53 in betel- and tobacco-related human oral cancer.The RING finger domain of MDM2 is essential for MDM2-mediated TGF-beta resistance.Mdm2 in growth signaling and cancer.Splicing up mdm2 for cancer proteome diversity.Different gene expression of MDM2, GAGE-1, -2 and FHIT in hepatocellular carcinoma and focal nodular hyperplasiaRegulation of p53--insights into a complex process.Signaling pathways involved in megakaryocyte-mediated proliferation of osteoblast lineage cells.Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2.The Many Faces of MDM2 Binding Partners.Human Oncoprotein MDM2 Up-regulates Expression of NF-κB2 Precursor p100 Conferring a Survival Advantage to Lung Cells.MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice.Cyclin a-CDK phosphorylation regulates MDM2 protein interactions.The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53.Human p53 and Hdm2: Cloning and Construction of Expression Plasmid
P2860
Q24793105-710CD584-C4C1-42E4-AF76-E176D7E19828Q28116100-212342FA-BC67-4B17-AE29-543281F0975FQ28119073-5BF7F428-DB27-4B36-80A1-FE433E7920A2Q28180384-2BEBB08D-EBF8-47AF-90D0-87DFE5111F1BQ28361370-4F7E19D3-49F3-461B-8A90-0119BA2121E1Q28366242-89D29F2E-77F7-445D-BC9E-F0B0D170C5CFQ28594666-4C94B24B-EEC5-43D3-8120-EA6E9B9C8FDDQ30812794-C0B97564-0001-4ADB-A638-615FD15102C0Q30832108-BCD9043A-29F5-4BEC-B2C9-0F118F1BF2F9Q33704559-913353FA-49B4-4755-BD1E-6AA96776F9D6Q33807793-640BEB17-B0A1-45F1-8A0B-521797705D26Q33957291-F2A0F4A9-60EC-4595-BAAB-6BF9D5D273CFQ33961803-C0654AA8-2BF4-45B9-AA57-71190EBC9248Q33964769-92CFB2A7-7659-4360-B069-C28B47442B83Q33997846-F92928DC-744F-4622-AC26-DEDC2BD8C1E3Q34335012-5C2B4FF6-3C9F-4D35-940A-AEB347ED1866Q34545941-C7A21B72-974C-45E1-B3C1-57A93AE89A9EQ34754561-6708D129-D76F-45D9-8BD6-B9F1663DC1CAQ35058579-64146AEA-715D-4800-92C2-FA26CEA4FB00Q35745704-434A241C-1728-4C17-88BD-2AB575C1F0D6Q35810677-429EA260-AAE6-4B07-BF81-12A2F5C14A1CQ36294472-36DF5DE1-9BCA-4EB0-982E-B9D922863784Q36387622-D1C06E79-3349-4CE5-B64F-3ABDE4E029C3Q36620133-638F0CBF-3FC6-4EB6-8C43-83C7B47ED962Q37636014-AD06DCF0-040C-4BDD-B22E-44219D11E7A3Q38304665-BC9E6CF9-0A05-444F-A255-9065BD4CD03CQ39879529-455A8FFC-4D2E-4C7B-B994-6289E2BFD5ABQ41287020-7E3A767F-5EB0-483C-BBD3-7C7863CC0D53Q42200663-013F8389-FE14-43C5-BAC7-D285ECC14051Q42468494-3B94FF8B-EAE6-4D3A-B75F-5AE5F3CE7557Q42828875-AD74DD1D-ED57-4834-99C2-1B7E8DB208D7Q43941701-5954B11E-272C-48DC-B928-843DC3E2E0C4Q52534736-D5E887C8-6587-40A1-8266-9636B403886EQ58131437-74237E36-EE82-4270-871D-9019EA0E5AD6
P2860
The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter
description
1997 nî lūn-bûn
@nan
1997 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
The MDM2 C-terminal region bin ...... ation of the cyclin A promoter
@ast
The MDM2 C-terminal region bin ...... ation of the cyclin A promoter
@en
The MDM2 C-terminal region bin ...... ation of the cyclin A promoter
@nl
type
label
The MDM2 C-terminal region bin ...... ation of the cyclin A promoter
@ast
The MDM2 C-terminal region bin ...... ation of the cyclin A promoter
@en
The MDM2 C-terminal region bin ...... ation of the cyclin A promoter
@nl
prefLabel
The MDM2 C-terminal region bin ...... ation of the cyclin A promoter
@ast
The MDM2 C-terminal region bin ...... ation of the cyclin A promoter
@en
The MDM2 C-terminal region bin ...... ation of the cyclin A promoter
@nl
P2860
P356
P1476
The MDM2 C-terminal region bin ...... ation of the cyclin A promoter
@en
P2093
T Léveillard
P2860
P304
P356
10.1074/JBC.272.49.30651
P407
P577
1997-12-05T00:00:00Z